14.28USD+1.06%Mkt Cap: 2.04B USDP/E: —Last update: 2026-05-26
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IP…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap2.04B USD
Enterprise Value1.84B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-42.76M USD
Revenue/Share—
Last Price14.28 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees34
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-25.39
PEG—
EV/EBITDA-34.95
EV/Revenue—
P/S—
P/B9.92
EPS (TTM)-0.32
EPS (Forward)-0.52
52W Range
5.38083% of range16.12
52W High16.12 USD
52W Low5.380 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-23.33%
ROA-22.10%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-42.09M USD
CapEx (TTM)12.00K USD
FCF Margin—
FCF Yield-1.40%
Net Debt-171.10M USD
Net Debt/EBITDA3.25
Balance Sheet
Debt/Equity0.00
Current Ratio24.75
Quick Ratio24.30
Book Value/Sh1.428 USD
Cash/Share1.210 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)23.45 USD
Target Range19.00 USD – 30.00 USD
# Analysts11
Ownership
Shares Out.141.98M
Float117.83M
Insiders0.63%
Institutions98.25%
Short Interest
Short Ratio8.9d
Short % Float11.96%
Short % Out.10.77%
Shares Short15.29M
Short (prev mo.)15.30M
Technical
SMA 5013.20 (+8.2%)
SMA 20011.17 (+27.8%)
Beta1.08
S&P 52W Chg28.31%
Avg Vol (30d)1.71M
Avg Vol (10d)1.34M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—